Ulcerative colitis (UC) is idiopathic, chronic, relapsing inflammation of the intestines with no effective line of treatment. Therefore, novel and safer drugs with sufficient therapeutic efficacy are needed. The aim of the current study is to investigate the effect of apremilast on histological outcome, inflammatory biomarkers and oxidative stress parameter in experimentally induced colitis. Material and method: Experimental colitis was induced in rats by 4% acetic acid (vol/vol) enemas. Rats with colitis were received either apremilast 25mg/kg or sulfasalazine 100mg/kg orally for 7days. Macroscopical and microscopical assessment and the measurement of the colonic cytokines (IL-4 and TNF-α), oxidative stress marker myeloperoxidase (MPO), and adhesion molecule (E-Selectin). Result: Results showed that both apremilast and sulfasalazine significantly reduced the macroscopical and histological injury in colon that induced by acetic acid. In addition to the downregulation of colonic proinflammatory cytokines, MPO and E-Selectin. Conclusion: These results concluded that artemisinin had effective role in experimental colitis in rats through anti-inflammatory and antioxidant actions with downregulation the colonic adhesive molecule E-Selectin.

• A. Martinez and C. Gil (2014).cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases, Expert Opin. Ther. Pat. 24; 1311–1321.
• Ansari MN, Ganaie MA., Ur Rehman N (2019). Protective role of Roflumilast against cadmium-induced cardiotoxicity through inhibition of oxidative stress and NF-jB signaling in rats. Saudi Ph J; 27; 5; 673-681.
• Anthoni C, Mennigen RB, Rijcken EJ, Laukotter MG, Spiegel HU (2006). Bosentan, an endothelin receptor antagonist, reduce leukocyte adhesion and inflammation in a murine model of inflammatory bowel disease. Int J Colorectal Dis; 21(5):409-18.
• Appleyard CB, Wallace JL (1995). Reactivation of hapten –induced colitis and its prevention by inflammatory drugs. Am J Physiol 269:G119-G125.
• Atarbashe R K and Ahmed A R (2020). The therapeutic effects of ambrisentan on experimentally induced colitis in a male rat’s models.Annals of Tropical Medicine and Public Health. 23, 4.
• Bertevello PL, Logullo ÂF, Nonogaki S, Campos FM ChiferiV(2005). Immunohistochemical assessment of mucosal cytokine profile in acetic acid Experimental Colitis. Clinics; 60(4):277-86.
• Braus NA, Elliott DE(2009). Advances in the pathogenesis and treatment of IBD. Clin Immunol.; 132 (1): 1-9.
• Chen W, Julie W Z Xu et al(2018). Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4+Foxp3+ Regulatory T Cells Differentiation. Front. Immunol. 9:1662.
• Cooper HS, Murthy SN, Shah RS (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest, 1993;69:238-49.
• Daniel WW (2009).Biostastics a foundation for analysis in the health sciences. 9th ed. Chapter seven:7.10, determinig sample size to control type II errors. P. 278.
• El-Ashmawy N E, Khedr N F, El-Bahrawy H A et al(2018). Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP. International Immunopharmacology 56; 36–42.
• Eskandari N, Mirmosayyeb O, Bordbari G, et al (2015). A short review on structure and role of cyclic-3′,5′-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool, J. Res. Pharm. Pract. 4; 175–181.
• Hernández-Rodríguez J, Segarra M, Vilardell C et al (2004). Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford); 43(3):294-301.
• Kasaian M T, Page K M, Fish S et al (2014).Therapeutic activity of an interleukin-4/ interleukin-13 dual antagonist on oxazolone-induced colitis in mice. Immunology, 143, 416–427.
• Khan A A, Alsahli M A, Rahmani A H (2018). Myeloperoxidase as an active disease biomarker: Recent biochemical and pathological perspectives. Med. Sci., 6, 33.
• Kim D H and Cheon J H (2017). Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies IMMUNE NETWORK. 17. 1: 25-40.
• Li H, Fan C, Feng C (2019). Inhibition of phosphodiesterase‐4 attenuates murine ulcerative colitis through interference with mucosal immunity. Br J Pharmacol. 176(13):2209-2226.
• Li H, ZuoJ, Tang W (2018). Phosphodiesterase‐4 inhibitors for the treatment of inflammatory diseases. Frontiers in Pharmacology, 9:1048.
• Loher F, Schmall K, Freytag P et al (2003).The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J Pharmacol Exp Ther 305: 549–556.
• Lopetuso L R, Gerardi v, Papa v et al (2017). Can We Predict the Efficacy of Anti-TNF-α Agents? Int. J. Mol. Sci. 18, 1973.
• Manna MJ, Abu-Raghif A, ALsaraf KM (2017). Therapeutic Effect of Sildenafil in Experimental Colitis through Anti-Oxidative Stress and Inhibition of Adhesion Molecules. J. Pharm.Sci. & Res. Vol. 9(9):1615-1623.
• Mao X,Yang Q,Chen D et al(2019).Benzoic acid used as food and feed additives can regulate gut functions. BioMed Research International,. 2019, Article ID 5721585, 6 pages.
• Mark A S and Peter M I (2016). The impact of updated NICE guidelines on biologic treatment of ulcerative colitis: reflections on past practices, the changing present and implications for the future. Journal Expert Opinion on Biological Therapy; 16(8): 975-977.
• Motavallian A, Minaiyan M, Rabbani M et al(2019). Anti-inflammatory effects of alosetron mediated through 5-HT3 receptors on experimental colitis; Research in Pharmaceutical Sciences, 14(3): 228-236.
• Paula V P, Seito LN, Di Stasi LC, et al(2012). Epicatechin Used in theTreatment of Intestinal Inflammatory Disease: An Analysis by Experimental Models. Evidence-Based Complementary and Alternative Medicine, Article ID; 508902, 12 pages).
• Puneet K R, Kavinder S, Nirmal S, et al (2014). A Review on Chemical-Induced Inflammatory Bowel Disease Models in Rodents.Korean J Physiol Pharmacol; 18(4):279-288.
• Raker V K, Becker C, Steinbrink K. (2016).The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases, Front. Immunol. 7;1–11.
• Rieder F, Siegmund B, Bundschuh D S(2013). The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice; PLOS ONE February; 8; 2;e56867.
• Robert A and Dale JE (1971). Prevention of duodenal ulcers in rats by feeding.Proc Soc Exp Biol Med;136(2): 439-40.
• Sakkas L I, Mavropoulos A. and Bogdanos D P. (2017). Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives. Curr Med Chem;24(28):3054-3067.
• Sanz M, Alvarez A, Piqueras L et al (2002). Rolipram inhibits leukocyte -endothelial cell interactions in vivo through P- and E-selectin downregulation; British Journal of Pharmacology vol 135 (8);1872 ± 1881.
• Sartor, R. B (2006). Mechanisms of disease: Pathogenesis of Crohn’s disease and ulcerative colitis. Nature Clinical Practice. Gastroenterology & Hepatology, 3(7), 390–407.
• Schafer P H, Parton A, Capone L (2014). Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal;. 26, 9, 2016–2029.
• Schafer P H, Adams M, Horan G et al(2019). Apremilast Normalizes Gene Expression of Infammatory Mediators in Human Keratinocytes and Reduces Antigen Induced Atopic Dermatitis in Mice. Drugs in R&D; 19:329–338.
• Spadaccini M, D’Alessio S, Peyrin-Biroulet L and Danese S (2017). PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue Int. J. Mol. Sci.;18, 1276.
• Tian T, Ziling W, and Jinhua Z(2017). Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid Med Cell Longe, 2017, Article ID 4535194, 18.
• Videla S, Vilaseca J, Medina C.et al(2006).Selective Inhibition of Phosphodiesterase -4 Ameliorates Chronic Colitis and Prevents Intestinal Fibrosis. JPET Vol. 316:940–945
• Wang Claire, Baer Hannah M,Gaya, Daniel R (2019). Can molecular stratification improve the treatment of inflammatory bowel disease?. Pharmacological Research; 148; 1043-6618.
• Xiao YT, Yan WH, Cao Y, Yan JK, and Cai, W (2016) “Neutralization of IL-6 and TNF-α ameliorates intestinal permeability in DSS-induced colitis,” Cytokine. 83, 189–192.
• Zhang D, Yan-Bo Ren, Kai Wei et al(2018).partitioned moxibustion alleviates colon injuries inulcerative colitis rats World J Gastroenterol; 24(30): 3384-3397.
• Zhang Y.-Z.and Li Y.-Y (2014). Inflammatory bowel disease: Pathogenesis.World J Gastroenterology; 20(1): 91–99.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.